ArticleAmerican journal of respiratory cell and molecular biology2021
A Recombinant Fragment of Human Surfactant Protein D Binds Spike Protein and Inhibits Infectivity and Replication of SARS-CoV-2 in Clinical Samples.
Article in American journal of respiratory cell and molecular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Hyperinflammation and immunomodulation in influenza, SARS-CoV-2 and syncytial respiratory virus infection in adults: from innate immune responses and biomarkers to clinical and therapeutic implications.Frontiers in microbiology · 2026Review
- The C-Type Lectin Receptors.Advances in experimental medicine and biology · 2025Review
- Innate Immune Response to Viral Infection.Advances in experimental medicine and biology · 2025Review
- Collectins and Ficolins.Advances in experimental medicine and biology · 2025Review
- Differential immunoregulation by human surfactant protein A variants determines severity of SARS-CoV-2-induced lung disease.Frontiers in immunology · 2025Article
- SARS-CoV-2 Lurking and Lingering in the Depths of Lungs.American journal of respiratory and critical care medicine · 2024Article
- Revisiting surfactant protein D: an immune surveillance molecule bridging innate and adaptive immunity.Frontiers in immunology · 2024Review
- Human surfactant protein A inhibits SARS-CoV-2 infectivity and alleviates lung injury in a mouse infection model.Frontiers in immunology · 2024Article
- Adsorption of pulmonary and exogeneous surfactants on SARS-CoV-2 spike protein.Journal of colloid and interface science · 2023Article
- Surfactant protein D inhibits growth, alters cell surface polysaccharide exposure and immune activation potential ofCell surface (Amsterdam, Netherlands) · 2022Article
- Review
- Review
- Host cell entry mediators implicated in the cellular tropism of SARS‑CoV‑2, the pathophysiology of COVID‑19 and the identification of microRNAs that can modulate the expression of these mediators (Review).International journal of molecular medicine · 2022Review
- Pulmonary surfactant as a versatile biomaterial to fight COVID-19.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- Review
- Response: Commentary: Pattern Recognition Proteins: First Line of Defense Against Coronaviruses.Frontiers in immunology · 2022Article
- Commentary: Pattern Recognition Proteins: First Line of Defense Against Coronaviruses.Frontiers in immunology · 2022Article
- Insights Gained Into the Treatment of COVID19 by Pulmonary Surfactant and Its Components.Frontiers in immunology · 2022Review
- Human surfactant protein D facilitates SARS-CoV-2 pseudotype binding and entry in DC-SIGN expressing cells, and downregulates spike protein induced inflammation.Frontiers in immunology · 2022Article
- SP-A binding to the SARS-CoV-2 spike protein using hybrid quantum and classical in silico modeling and molecular pruning by Quantum Approximate Optimization Algorithm (QAOA) Based MaxCut with ZDOCK.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease (COVID-19) is an acute infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Human SP-D (surfactant protein D) is known to interact with the spike protein of SARS-CoV, but its immune surveillance against SARS-CoV-2 is not known. The current study aimed to examine the potential of a recombinant fragment of human SP-D (rfhSP-D) as an inhibitor of replication and infection of SARS-CoV-2. The interaction of rfhSP-D with the spike protein of SARS-CoV-2 and human ACE-2 (angiotensin-converting enzyme 2) receptor was predicted via docking analysis. The inhibition of interaction between the spike protein and ACE-2 by rfhSP-D was confirmed using direct and indirect ELISA. The effect of rfhSP-D on replication and infectivity of SARS-CoV-2 from clinical samples was assessed by measuring the expression of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.